Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
IRAK-4 Pipeline Products Market Report Overview
Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. The ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
The IRAK-4 pipeline market research report provides comprehensive information on the therapeutics under development for IRAK-4, with analysis by stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for IRAK-4 and features dormant and discontinued products.
IRAK-4 Pipeline Products Market Segmentation by Therapy Area
The key therapy areas in the IRAK-4 pipeline products market include immunology, oncology, dermatology, gastrointestinal, and others. Immunology has the highest share in the pipeline.
IRAK-4 Pipeline Products Market Analysis by Therapy Area
For more therapy area insights into the IRAK-4 pipeline products market, download a free report sample
IRAK-4 Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanism of action in the IRAK-4 pipeline products market is Interleukin 1 Receptor Associated Kinase 4 Inhibitor.
IRAK-4 Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the IRAK-4 pipeline products market are oral, topical, and intravenous. Oral is the leading RoA.
IRAK-4 Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the IRAK-4 pipeline products market, download a free report sample
IRAK-4 Pipeline Products Market Segmentation by Molecule Types
The key molecule type in the IRAK-4 pipeline products market is the small molecule.
IRAK-4 Pipeline Products Market - Competitive Landscape
Some of the leading companies in the IRAK-4 pipeline products market are Kymera Therapeutics Inc, Rigel Pharmaceuticals Inc, Asahi Kasei Pharma Corp, Astellas Pharma Inc, AstraZeneca Plc, and others. Kymera Therapeutics Inc has the highest number of products in the pipeline.
IRAK-4 Pipeline Products Market Analysis by Companies
To know more about the leading players in the IRAK-4 pipeline products market, download a free report sample
IRAK-4 Pipeline Products Market Report Overview
Key Therapy Areas | Immunology, Oncology, Dermatology, Gastrointestinal, and Others |
Key Mechanism of Action | Interleukin 1 Receptor Associated Kinase 4 Inhibitor |
Key Route of Administration | Oral, Topical, And Intravenous |
Key Molecule Type | Small Molecule |
Leading Companies | Kymera Therapeutics Inc, Rigel Pharmaceuticals Inc, Asahi Kasei Pharma Corp, Astellas Pharma Inc, AstraZeneca Plc, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Interleukin 1 Receptor Associated Kinase 4.
- The pipeline guide reviews pipeline therapeutics for Interleukin 1 Receptor Associated Kinase 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Interleukin 1 Receptor Associated Kinase 4 therapeutics and enlists all their major and minor products for the indication.
- The pipeline guide evaluates Interleukin 1 Receptor Associated Kinase 4 therapeutics based on their mechanism of action (MoA), route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline products.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Interleukin 1 Receptor Associated Kinase 4
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Interleukin 1 Receptor Associated Kinase 4.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies in the Interleukin 1 Receptor Associated Kinase 4 market.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Interleukin 1 Receptor Associated Kinase 4 pipeline depth and the focus of therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive products to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued products and apply this knowledge to pipeline development.
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Emmaus Life Sciences Inc
Evommune Inc
Fresh Tracks Therapeutics Inc
Gilead Sciences Inc
Kurome Therapeutics Inc
Kymera Therapeutics Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Xi'An Yufan Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the IRAK-4 pipeline products market?
The key therapy areas in the IRAK-4 pipeline products market include immunology, oncology, dermatology, gastrointestinal, and others.
-
What is the key mechanism of action in the IRAK-4 pipeline products market?
The key mechanism of action in the IRAK-4 pipeline products market is Interleukin 1 Receptor Associated Kinase 4 Inhibitor.
-
What are the key routes of administration in the IRAK-4 pipeline products market?
The key routes of administration in the IRAK-4 pipeline products market are oral, topical, and intravenous.
-
What is the key molecule type in the IRAK-4 pipeline products market?
The key molecule type in the IRAK-4 pipeline products market is the small molecule.
-
Which are the leading companies in the IRAK-4 pipeline products market?
Some of the leading companies in the IRAK-4 pipeline products market are Kymera Therapeutics Inc, Rigel Pharmaceuticals Inc, Asahi Kasei Pharma Corp, Astellas Pharma Inc, AstraZeneca Plc, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.